Dr. Cao will serve as a member of the Audit Committee and the Compensation Committee of the Board.Dr. Ken Takeshita is a recognized biopharmaceutical executive and clinical development expert, with experience as a practicing oncologist and investigator. He is the Global Head of Research & Development for Daiichi Sankyo, responsible for leading the organization?s global research and clinical development strategy. His previous roles include senior R&D and global clinical leadership positions at Kite Pharma (now part of Gilead Sciences Inc.), Sorrento Therapeutics, Celgene Corporation (now part of Bristol-Myers Squibb Company), and Amgen. Previously, Dr. Takeshita served on the faculty in Hematology at Yale University School of Medicine and New York University School of Medicine. Dr. Takeshita completed his MD at Yale University and post-doctoral training at Yale and the University of Tokyo.